Oxford Biomedica/£OXB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Oxford Biomedica
- Ticker
- £OXB
- Sector
- Health
- Primary listing
- LSE
- Employees
- 1,017
- Headquarters
- Oxford, United Kingdom
- Website
- www.oxb.com
Oxford Biomedica Metrics
BasicAdvanced
£644M
-
-£0.34
1.09
-
Price and volume
Market cap
£644M
Beta
1.09
52-week high
£9.62
52-week low
£4.20
Average daily volume
396K
Financial strength
Current ratio
2.211
Quick ratio
1.764
Long term debt to equity
2.608
Total debt to equity
2.731
Interest coverage (TTM)
-1.93%
Profitability
EBITDA (TTM)
-22.721
Gross margin (TTM)
36.19%
Net profit margin (TTM)
-23.23%
Operating margin (TTM)
-16.52%
Effective tax rate (TTM)
3.31%
Revenue per employee (TTM)
£170,000
Management effectiveness
Return on assets (TTM)
-7.03%
Return on equity (TTM)
-89.69%
Valuation
Price to revenue (TTM)
3.625
Price to book
11.08
Price to tangible book (TTM)
19.05
Price to free cash flow (TTM)
-20.541
Free cash flow yield (TTM)
-4.87%
Free cash flow per share (TTM)
-0.259
Growth
Revenue change (TTM)
15.97%
Earnings per share change (TTM)
-4.66%
3-year revenue growth (CAGR)
13.79%
10-year revenue growth (CAGR)
22.00%
3-year earnings per share growth (CAGR)
-18.96%
10-year earnings per share growth (CAGR)
0.91%
What the Analysts think about Oxford Biomedica
Analyst ratings (Buy, Hold, Sell) for Oxford Biomedica stock.
Analyst projections of the future price of Oxford Biomedica stock.
Bulls say / Bears say
Revenue rose 9% to £79.8 million in the first half of 2026, with manufacturing services up 20%, showing that demand is translating into higher sales. (OXB)
OXB signed 17 new clients in H1 and reported a pipeline up about 30% year on year to $713 million. Its portfolio has broadened to 50 clients and 59 programmes, which could support growth and reduce reliance on individual customers. (OXB)
The Durham site is now GMP-ready and has completed its first GMP manufacturing run, adding US capacity and a platform for future client work. OXB also reported that about £168 million of forecast 2026 revenue was covered by contracted client orders as of September. (OXB)
OXB cut its 2026 revenue forecast to £180–200 million from £220–240 million after client programme delays and changes to a major customer’s procurement plans. Durham’s operational readiness was also six months late, highlighting execution and forecasting risk. (Reuters)
First-half gross margin fell to 37% from 43%, while the operating loss widened to £29.1 million and included a £7.6 million impairment at the French operations. This suggests that weaker site utilisation and mix are weighing on returns despite revenue growth. (London Stock Exchange)
Cash fell to £75.3 million from £96.9 million at the end of 2025, and net cash dropped to £21.4 million from £55.4 million as operating cash flow was consumed. The company has drawn on its Oaktree loan facility, while its own downside planning allows for investment cuts, site rationalisation and workforce reductions if forecast cash flows fail to materialise. (London Stock Exchange)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Oxford Biomedica Financial Performance
Revenues and expenses
Oxford Biomedica Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Oxford Biomedica
AllGBPUSD
Fund name | Fund size | £OXB weighting |
|---|---|---|
Vanguard FTSE 250£VMID | £1.5B | 0.13% |
Vanguard FTSE 250£VMIG | £569M | 0.13% |
iShares FTSE 250£MIDD | £672M | 0.13% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.06% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.06% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.